Psychedelics in the Clinical Setting: The Potential for Harm and the Promise of Healing
There are a number of unique issues that psychedelics present in a clinical setting that are yet to be adequately addressed.

There are a number of unique issues that psychedelics present in a clinical setting that are yet to be adequately addressed.

A rundown of the major legal questions at play in the New York Times-OpenAI lawsuit.

This concluding post attempts to synthesize contributions to the symposium “From Principles to Practice: Human Rights and Public Health Emergencies”

Neglected tropical diseases were at the forefront of a recent convening on human health and climate change.

Scholars, analysts, and companies cannot agree on what Amgen v. Sanofi means for patients, drug makers, and innovation.

SCOTUS revisits enablement, but Amgen v. Sanofi probably won’t transform patent law on its own.

The Principles set forth a human rights-based solidarity approach to limit the harmful effects of serious health crises.

A combination of high demand and a patent monopoly has created a perfect storm of profitability for Janssen’s Spravato.

The Malawian courts largely have embraced the human rights obligations within the context of public health emergencies detailed in the Principles.
